Tenax Therapeutics, Inc. (TENX:NASDAQ) closed at $1.69 on November 10, 2026, down 5.06% on the day. The stock trades 91.3% below its 52-week high of $19.40 and 29.0% above its 52-week low of $1.31. Over the past year, it lost 76.0%. Tenax Therapeutics, Inc. is part of the Health Care sector (Biotechnology: Commercial Physical & Biological Resarch).
In 252 trading sessions since November 10, 2025, TENX closed higher on 122 days (48%). Its best day was March 10, 2026 (+31.67%) and its worst was August 10, 2026 (-89.77%). The stock moved 10% or more in a single session 18 times. It opened at least 5% above the previous day's high 3 times.
Tenax Therapeutics, Inc., a specialty pharmaceutical company, focused on the development and commercialization of a portfolio of products for the critical care market in the United States and Canada. It focuses on the development and commercialization of pharmaceutical products containing levosimendan, 2.5 mg/ml concentrate for solution for infusion/5ml vial for use in the reduction of morbidity and mortality in cardiac surgery patients at risk for developing Low Cardiac Output Syndrome. The company offers Wundecyte, a wound-healing gel. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. Tenax Therapeutics, Inc. was founded in 1967 and is headquartered in Morrisville, North Carolina.
Find more stocks like TENX with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.